Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration.

Abstract

PURPOSE:

To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration.

METHODS:

This retrospective review included patients who received pegaptanib combined with 165 microg of moxifloxacin every 6 weeks. Ophthalmic examination was performed, and adverse events were recorded at each visit; additional assessments (e.g., optical coherence tomography) were performed when indicated.

RESULTS:

Eighty eyes of 65 patients were identified; the median length of follow-up was 13.2 months (range, 10-16 months), and eyes received an average of 6 injections (range, 4-9 months). Seventy eyes of 80 patients have been followed for >or=1 year; 80% (65/70) had stable or improved vision, and 97% (68/70) lost <15 letters of vision.

CONCLUSION:

Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration.

• Authors: Michael D Bennett, Wendy Yee, J Shepard Bryan
• Journal: Retina (Philadelphia, Pa.) (Retina) 2008 Jul-Aug Vol. 28 Issue 7 Pg. 976-80 ISSN: 0275-004X [Print] United States
• PMID: 18698300 (Publication Type: Journal Article)

Chemical References

• Anti-Infective Agents
• Aptamers, Nucleotide
• Aza Compounds
• Fluoroquinolones
• Quinolines
• Vascular Endothelial Growth Factor A
• pegaptanib
• Moxifloxacin

Topics

• Aged
• Aged, 80 and over
• Anti-Infective Agents (therapeutic use)
• Aptamers, Nucleotide (therapeutic use)
• Aza Compounds (therapeutic use)
• Choroidal Neovascularization (drug therapy, etiology)
• Drug Therapy, Combination
• Female
• Fluoroquinolones
• Follow-Up Studies
• Humans
• Injections
• Macular Degeneration (complications, drug therapy)
• Male
• Middle Aged
• Moxifloxacin
• Quinolines (therapeutic use)
• Retrospective Studies
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity
• Vitreous Body